Background Paclitaxel-eluting stent (Taxus) was introduced in Korea about 1 year ago. Clinical and angiographic outcome in Korea at 1 year are unknown. Method and results Total 457 lesions which was treated with Taxus from 7 hospitals from April,2003 to May, 2004 were evaluated. Mean age was 61.8 years and the proportion of female was 28.6 %. DM patient was 37.2%. Mean reference diameter was 2.89짹0.54mm and length was 20.19짹10.08 mm. AHA type B2 lesion was 43.9% and C was 39.5%. Subacute thrombosis was developed in 6 lesions (1.3%) and 6 month MACE rate including TVR was 8.7 %. 5 of 6 subacute thrombosis cases had DM. But lesion type, sex, and other cardiovascular risk factors did not have an effect on development of subacute thrombosis. In 12 month clinical follow-up, another MACE was not reported. Follow up angiography was performed in 119 lesions. Late loss was 0.42짹0.75mm and the binary in-stent restenosis rate was 11.8 %. The restenosis rate was higher than data from TAXUS-IV, it may be due to higher prevalence of the complex lesion (type B2 and C lesion : 83.4%) and DM patients(37.2 vs. 31.1%). There was no significant difference between patent and in-stent restenosis group in age, sex, past history , lesion length, and lesion diameter. But in ISR group, the prevalence of type C lesion was higher (64.7 vs. 41.9%,p<0.05) than in patent group. Conclusion In more complex lesion compared with TAXUS-IV study, paclitaxel-eluting stent is safe and still showed lower rate of in-stent restenosis and MACE comparing with bare metal stent.